© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to April
EGFR-sparing HER2 kinase inhibitor
approved in met. HER2+ BC incl. w/ brain met.
from optimization of known TKIs
Mol. Cancer Ther., Apr. 1, 2020
Array / Cascadian Tx / Seattle Genetics
Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the closely related EGFR, which is hypothesized to be a…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.